Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Randomized Controlled Trials as Topic | 29 | 2024 | 9959 | 2.610 |
Why?
|
Causality | 13 | 2023 | 1275 | 2.470 |
Why?
|
Meta-Analysis as Topic | 7 | 2020 | 1344 | 1.560 |
Why?
|
Models, Statistical | 7 | 2024 | 5102 | 1.420 |
Why?
|
Research Design | 12 | 2023 | 5987 | 1.240 |
Why?
|
Statistics as Topic | 3 | 2021 | 2373 | 0.950 |
Why?
|
Propensity Score | 6 | 2020 | 1781 | 0.880 |
Why?
|
Models, Theoretical | 3 | 2023 | 3589 | 0.860 |
Why?
|
Janus Kinase 2 | 4 | 2009 | 528 | 0.830 |
Why?
|
Myocardial Infarction | 9 | 2024 | 11727 | 0.770 |
Why?
|
Citrus sinensis | 1 | 2020 | 16 | 0.760 |
Why?
|
Lung Neoplasms | 11 | 2024 | 13102 | 0.750 |
Why?
|
Malus | 1 | 2020 | 48 | 0.730 |
Why?
|
Morals | 1 | 2023 | 284 | 0.730 |
Why?
|
Comparative Effectiveness Research | 4 | 2018 | 681 | 0.660 |
Why?
|
Influenza Vaccines | 2 | 2023 | 738 | 0.660 |
Why?
|
Review Literature as Topic | 3 | 2015 | 336 | 0.630 |
Why?
|
Patient Selection | 4 | 2019 | 4215 | 0.630 |
Why?
|
Data Interpretation, Statistical | 6 | 2021 | 2716 | 0.620 |
Why?
|
Pharmacoepidemiology | 1 | 2021 | 323 | 0.610 |
Why?
|
Influenza, Human | 3 | 2023 | 1479 | 0.610 |
Why?
|
Benchmarking | 3 | 2022 | 1042 | 0.600 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2021 | 5221 | 0.600 |
Why?
|
Hypereosinophilic Syndrome | 2 | 2008 | 93 | 0.590 |
Why?
|
Evidence-Based Practice | 2 | 2019 | 500 | 0.580 |
Why?
|
Monte Carlo Method | 1 | 2022 | 1254 | 0.580 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2018 | 194 | 0.580 |
Why?
|
Nutrition Surveys | 2 | 2023 | 1660 | 0.580 |
Why?
|
Proton Pump Inhibitors | 1 | 2021 | 526 | 0.530 |
Why?
|
Gene Dosage | 2 | 2010 | 1252 | 0.520 |
Why?
|
Databases, Bibliographic | 1 | 2015 | 128 | 0.500 |
Why?
|
Cathartics | 1 | 2015 | 125 | 0.490 |
Why?
|
Technology Assessment, Biomedical | 1 | 2016 | 306 | 0.480 |
Why?
|
Cost Sharing | 1 | 2018 | 407 | 0.480 |
Why?
|
Likelihood Functions | 2 | 2017 | 1005 | 0.470 |
Why?
|
Medicare | 8 | 2023 | 6566 | 0.450 |
Why?
|
Humans | 104 | 2024 | 744343 | 0.450 |
Why?
|
Medicare Part C | 1 | 2018 | 296 | 0.450 |
Why?
|
Probability | 5 | 2023 | 2505 | 0.440 |
Why?
|
Critical Illness | 2 | 2024 | 2670 | 0.440 |
Why?
|
Asymptomatic Diseases | 2 | 2014 | 551 | 0.420 |
Why?
|
Antineoplastic Agents | 9 | 2021 | 13695 | 0.400 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1411 | 0.390 |
Why?
|
Stroke | 8 | 2016 | 9981 | 0.380 |
Why?
|
Watchful Waiting | 2 | 2012 | 492 | 0.380 |
Why?
|
Foramen Ovale, Patent | 4 | 2016 | 223 | 0.380 |
Why?
|
Genes, p53 | 1 | 2013 | 755 | 0.380 |
Why?
|
Aryldialkylphosphatase | 1 | 2010 | 63 | 0.380 |
Why?
|
Heart Diseases | 1 | 2024 | 2788 | 0.370 |
Why?
|
Genes, erbB-2 | 1 | 2011 | 162 | 0.370 |
Why?
|
Coronary Artery Disease | 5 | 2021 | 6487 | 0.370 |
Why?
|
Coitus | 1 | 2011 | 133 | 0.370 |
Why?
|
Rectum | 1 | 2015 | 904 | 0.370 |
Why?
|
Carotid Stenosis | 2 | 2014 | 854 | 0.360 |
Why?
|
Research Report | 1 | 2013 | 355 | 0.360 |
Why?
|
Hypolipidemic Agents | 1 | 2014 | 604 | 0.360 |
Why?
|
Computer Simulation | 6 | 2023 | 6196 | 0.350 |
Why?
|
Weight-Bearing | 1 | 2011 | 515 | 0.340 |
Why?
|
Pneumonia | 1 | 2021 | 2133 | 0.330 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2008 | 379 | 0.330 |
Why?
|
ABO Blood-Group System | 1 | 2011 | 367 | 0.330 |
Why?
|
ras Proteins | 2 | 2011 | 1060 | 0.320 |
Why?
|
Polymorphism, Genetic | 5 | 2013 | 4328 | 0.320 |
Why?
|
Parity | 1 | 2011 | 929 | 0.320 |
Why?
|
Abortion, Habitual | 1 | 2008 | 70 | 0.320 |
Why?
|
Cardiac Surgical Procedures | 2 | 2021 | 3537 | 0.320 |
Why?
|
Colorectal Neoplasms | 5 | 2013 | 6773 | 0.310 |
Why?
|
Glutathione Transferase | 1 | 2010 | 595 | 0.310 |
Why?
|
Sample Size | 2 | 2021 | 845 | 0.310 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2018 | 1209 | 0.300 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2007 | 98 | 0.300 |
Why?
|
Diagnostic Tests, Routine | 1 | 2013 | 783 | 0.300 |
Why?
|
Mutation | 8 | 2011 | 29786 | 0.300 |
Why?
|
Thrombocythemia, Essential | 1 | 2008 | 105 | 0.300 |
Why?
|
Colon | 1 | 2015 | 1772 | 0.290 |
Why?
|
SEER Program | 3 | 2021 | 1508 | 0.290 |
Why?
|
Polycythemia Vera | 1 | 2008 | 164 | 0.290 |
Why?
|
Mammography | 1 | 2018 | 2476 | 0.290 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2007 | 56 | 0.280 |
Why?
|
Death, Sudden, Cardiac | 2 | 2014 | 1541 | 0.280 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1439 | 0.280 |
Why?
|
Databases, Factual | 4 | 2018 | 7729 | 0.280 |
Why?
|
Preoperative Care | 1 | 2015 | 2250 | 0.270 |
Why?
|
Genetic Predisposition to Disease | 4 | 2011 | 17446 | 0.270 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2006 | 110 | 0.270 |
Why?
|
Sepsis | 1 | 2020 | 2593 | 0.270 |
Why?
|
Musculoskeletal Diseases | 1 | 2011 | 581 | 0.260 |
Why?
|
Positron-Emission Tomography | 4 | 2014 | 6234 | 0.260 |
Why?
|
Atrial Fibrillation | 2 | 2022 | 5034 | 0.260 |
Why?
|
Organoplatinum Compounds | 1 | 2006 | 408 | 0.250 |
Why?
|
Thoracic Wall | 1 | 2007 | 203 | 0.250 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 7913 | 0.250 |
Why?
|
Fibrinolytic Agents | 1 | 2014 | 2158 | 0.250 |
Why?
|
Nose Neoplasms | 1 | 2007 | 246 | 0.250 |
Why?
|
Thiazolidinediones | 1 | 2008 | 476 | 0.250 |
Why?
|
Thoracic Neoplasms | 1 | 2007 | 268 | 0.240 |
Why?
|
Antibodies, Monoclonal | 4 | 2011 | 9274 | 0.240 |
Why?
|
Decision Making | 2 | 2018 | 3887 | 0.240 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4034 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 5 | 2010 | 5535 | 0.230 |
Why?
|
Biomedical Research | 3 | 2019 | 3309 | 0.220 |
Why?
|
Point Mutation | 1 | 2008 | 1623 | 0.210 |
Why?
|
Risk Factors | 13 | 2021 | 72290 | 0.210 |
Why?
|
Confidence Intervals | 4 | 2011 | 2971 | 0.200 |
Why?
|
Acute Coronary Syndrome | 2 | 2012 | 2337 | 0.200 |
Why?
|
Proto-Oncogene Proteins | 2 | 2011 | 4554 | 0.200 |
Why?
|
Evidence-Based Medicine | 5 | 2018 | 3610 | 0.200 |
Why?
|
Intestinal Perforation | 1 | 2023 | 253 | 0.190 |
Why?
|
Treatment Outcome | 13 | 2023 | 63114 | 0.190 |
Why?
|
Oximetry | 1 | 2024 | 471 | 0.190 |
Why?
|
Survival Rate | 7 | 2021 | 12788 | 0.190 |
Why?
|
Neoplasm Staging | 5 | 2021 | 11031 | 0.180 |
Why?
|
North America | 1 | 2024 | 1249 | 0.180 |
Why?
|
Myelodysplastic Syndromes | 1 | 2010 | 1352 | 0.180 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2010 | 2948 | 0.180 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2007 | 1581 | 0.170 |
Why?
|
Policy | 1 | 2023 | 508 | 0.170 |
Why?
|
United States | 12 | 2023 | 69872 | 0.170 |
Why?
|
Coronary Thrombosis | 1 | 2022 | 495 | 0.170 |
Why?
|
Coronary Artery Bypass | 2 | 2019 | 2289 | 0.170 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2023 | 341 | 0.170 |
Why?
|
Eligibility Determination | 1 | 2022 | 403 | 0.170 |
Why?
|
Data Mining | 2 | 2014 | 537 | 0.170 |
Why?
|
Nursing Homes | 2 | 2023 | 1036 | 0.170 |
Why?
|
Case-Control Studies | 5 | 2021 | 21746 | 0.160 |
Why?
|
Regression Analysis | 2 | 2023 | 6459 | 0.160 |
Why?
|
Aged | 16 | 2023 | 163280 | 0.160 |
Why?
|
Odds Ratio | 4 | 2011 | 9849 | 0.150 |
Why?
|
Infant, Newborn, Diseases | 1 | 2023 | 582 | 0.150 |
Why?
|
Electronic Health Records | 1 | 2014 | 4468 | 0.150 |
Why?
|
Genetic Association Studies | 3 | 2011 | 2703 | 0.150 |
Why?
|
Infant, Premature, Diseases | 1 | 2023 | 706 | 0.150 |
Why?
|
Early Detection of Cancer | 2 | 2024 | 3086 | 0.150 |
Why?
|
PubMed | 2 | 2015 | 123 | 0.150 |
Why?
|
Bayes Theorem | 2 | 2017 | 2309 | 0.150 |
Why?
|
Female | 30 | 2023 | 380194 | 0.150 |
Why?
|
Validation Studies as Topic | 1 | 2017 | 159 | 0.140 |
Why?
|
Live Birth | 1 | 2020 | 512 | 0.140 |
Why?
|
Hydroxyurea | 2 | 2008 | 290 | 0.140 |
Why?
|
Shock, Septic | 1 | 2023 | 775 | 0.140 |
Why?
|
Therapeutics | 1 | 2016 | 116 | 0.140 |
Why?
|
Brain Ischemia | 1 | 2010 | 3265 | 0.140 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2014 | 2649 | 0.140 |
Why?
|
Authorship | 1 | 2019 | 271 | 0.140 |
Why?
|
Delivery of Health Care | 1 | 2014 | 5319 | 0.140 |
Why?
|
Fever of Unknown Origin | 1 | 2016 | 93 | 0.140 |
Why?
|
Anticoagulants | 4 | 2021 | 4599 | 0.130 |
Why?
|
Fertility | 1 | 2020 | 781 | 0.130 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 2872 | 0.130 |
Why?
|
Hydrocortisone | 1 | 2023 | 1826 | 0.130 |
Why?
|
Critical Care | 2 | 2020 | 2647 | 0.130 |
Why?
|
Septal Occluder Device | 1 | 2016 | 128 | 0.130 |
Why?
|
Access to Information | 1 | 2018 | 320 | 0.130 |
Why?
|
Enema | 1 | 2015 | 141 | 0.130 |
Why?
|
Cardiovascular Agents | 1 | 2021 | 850 | 0.120 |
Why?
|
Exercise | 1 | 2011 | 5615 | 0.120 |
Why?
|
Middle Aged | 18 | 2024 | 213383 | 0.120 |
Why?
|
Breast Neoplasms | 3 | 2013 | 20822 | 0.120 |
Why?
|
Calibration | 1 | 2017 | 816 | 0.120 |
Why?
|
Heparin | 1 | 2021 | 1637 | 0.120 |
Why?
|
Reproducibility of Results | 5 | 2016 | 19905 | 0.120 |
Why?
|
Survival Analysis | 2 | 2021 | 10252 | 0.110 |
Why?
|
Human papillomavirus 18 | 1 | 2014 | 128 | 0.110 |
Why?
|
Random Allocation | 1 | 2018 | 2429 | 0.110 |
Why?
|
Law Enforcement | 1 | 2014 | 109 | 0.110 |
Why?
|
Colonic Neoplasms | 2 | 2020 | 2541 | 0.110 |
Why?
|
Nuclear Medicine | 1 | 2016 | 233 | 0.110 |
Why?
|
Heart-Assist Devices | 1 | 2023 | 1194 | 0.110 |
Why?
|
Prenatal Care | 1 | 2020 | 1092 | 0.110 |
Why?
|
Genes, myc | 1 | 2014 | 399 | 0.110 |
Why?
|
Postoperative Complications | 1 | 2015 | 15295 | 0.110 |
Why?
|
Prognosis | 8 | 2020 | 29063 | 0.110 |
Why?
|
Police | 1 | 2014 | 149 | 0.110 |
Why?
|
Sensitivity and Specificity | 4 | 2017 | 14722 | 0.110 |
Why?
|
Human papillomavirus 16 | 1 | 2014 | 262 | 0.110 |
Why?
|
Endarterectomy, Carotid | 2 | 2014 | 546 | 0.110 |
Why?
|
Oxygen | 1 | 2024 | 4189 | 0.110 |
Why?
|
Prostatic Neoplasms | 2 | 2012 | 11124 | 0.100 |
Why?
|
Digital Rectal Examination | 1 | 2012 | 42 | 0.100 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 12261 | 0.100 |
Why?
|
Angioplasty | 1 | 2014 | 364 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15519 | 0.100 |
Why?
|
Male | 21 | 2023 | 350118 | 0.100 |
Why?
|
Drug-Eluting Stents | 1 | 2018 | 753 | 0.100 |
Why?
|
Proline | 1 | 2013 | 458 | 0.100 |
Why?
|
Disease-Free Survival | 3 | 2014 | 6895 | 0.100 |
Why?
|
Bibliometrics | 1 | 2015 | 339 | 0.100 |
Why?
|
Loss of Heterozygosity | 1 | 2013 | 684 | 0.100 |
Why?
|
Algorithms | 2 | 2022 | 13881 | 0.090 |
Why?
|
Lymphoma | 2 | 2010 | 1877 | 0.090 |
Why?
|
Alleles | 2 | 2013 | 6933 | 0.090 |
Why?
|
Classification | 1 | 2011 | 129 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2023 | 3528 | 0.090 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39050 | 0.090 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2018 | 1873 | 0.090 |
Why?
|
Veterans | 1 | 2024 | 2519 | 0.090 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4851 | 0.090 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1265 | 0.090 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 407 | 0.090 |
Why?
|
Skull | 1 | 2014 | 813 | 0.090 |
Why?
|
Chronic Disease | 2 | 2019 | 9146 | 0.090 |
Why?
|
Administration, Oral | 2 | 2015 | 3913 | 0.090 |
Why?
|
Logistic Models | 2 | 2022 | 13408 | 0.090 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15165 | 0.090 |
Why?
|
Telomerase | 1 | 2014 | 730 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8642 | 0.080 |
Why?
|
Risk | 2 | 2011 | 9687 | 0.080 |
Why?
|
Registries | 2 | 2022 | 8089 | 0.080 |
Why?
|
Aorta | 1 | 2017 | 2061 | 0.080 |
Why?
|
Sex Factors | 2 | 2021 | 10397 | 0.080 |
Why?
|
Peptide Fragments | 1 | 2021 | 5097 | 0.080 |
Why?
|
Adult | 13 | 2024 | 214055 | 0.080 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 25043 | 0.080 |
Why?
|
Epidemiologic Studies | 1 | 2011 | 676 | 0.080 |
Why?
|
Health Expenditures | 1 | 2021 | 2348 | 0.080 |
Why?
|
Glioma | 2 | 2013 | 3401 | 0.080 |
Why?
|
Sjogren's Syndrome | 1 | 2009 | 233 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20129 | 0.080 |
Why?
|
Genetic Heterogeneity | 1 | 2010 | 733 | 0.070 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2011 | 388 | 0.070 |
Why?
|
Age Factors | 3 | 2021 | 18370 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2021 | 57776 | 0.070 |
Why?
|
Cytogenetic Analysis | 1 | 2007 | 295 | 0.070 |
Why?
|
Genetic Markers | 2 | 2010 | 2634 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2023 | 6489 | 0.070 |
Why?
|
Quinazolines | 2 | 2010 | 1356 | 0.070 |
Why?
|
Morbidity | 1 | 2012 | 1769 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 1692 | 0.070 |
Why?
|
Disease Progression | 3 | 2012 | 13284 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2014 | 1471 | 0.070 |
Why?
|
Genotype | 2 | 2011 | 12951 | 0.070 |
Why?
|
Genes, ras | 1 | 2008 | 690 | 0.070 |
Why?
|
Cross-Over Studies | 1 | 2011 | 2029 | 0.070 |
Why?
|
Stents | 2 | 2014 | 3280 | 0.070 |
Why?
|
Hematologic Diseases | 1 | 2009 | 498 | 0.070 |
Why?
|
Periodicals as Topic | 2 | 2013 | 1432 | 0.060 |
Why?
|
HIV Infections | 2 | 2022 | 16718 | 0.060 |
Why?
|
Prostate-Specific Antigen | 2 | 2012 | 2494 | 0.060 |
Why?
|
Risk Assessment | 4 | 2016 | 23338 | 0.060 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2015 | 3068 | 0.060 |
Why?
|
Immunoenzyme Techniques | 1 | 2008 | 1799 | 0.060 |
Why?
|
Treatment Failure | 1 | 2011 | 2618 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2010 | 5172 | 0.060 |
Why?
|
Nasal Cavity | 1 | 2007 | 313 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 35421 | 0.060 |
Why?
|
Neoplasms | 1 | 2013 | 21683 | 0.060 |
Why?
|
RNA | 1 | 2014 | 2749 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7785 | 0.060 |
Why?
|
Gene Amplification | 1 | 2008 | 1063 | 0.060 |
Why?
|
Fludrocortisone | 1 | 2023 | 25 | 0.060 |
Why?
|
Endometrial Neoplasms | 1 | 2013 | 1353 | 0.060 |
Why?
|
Biopsy | 2 | 2013 | 6756 | 0.060 |
Why?
|
Low Back Pain | 1 | 2011 | 956 | 0.050 |
Why?
|
Prednisone | 1 | 2007 | 1574 | 0.050 |
Why?
|
Consensus | 2 | 2023 | 2959 | 0.050 |
Why?
|
Knee Joint | 1 | 2011 | 1680 | 0.050 |
Why?
|
Lumbar Vertebrae | 1 | 2011 | 1848 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2020 | 6364 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5256 | 0.050 |
Why?
|
Benzamides | 1 | 2007 | 1379 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 2020 | 0.050 |
Why?
|
Methotrexate | 1 | 2008 | 1727 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2007 | 1420 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3507 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2013 | 8863 | 0.050 |
Why?
|
Infusions, Intravenous | 1 | 2006 | 2274 | 0.050 |
Why?
|
Rehabilitation Centers | 1 | 2023 | 254 | 0.050 |
Why?
|
Stem Cell Transplantation | 1 | 2010 | 1620 | 0.050 |
Why?
|
Motor Activity | 1 | 2011 | 2714 | 0.050 |
Why?
|
Laparotomy | 1 | 2023 | 473 | 0.050 |
Why?
|
Cell Division | 1 | 2008 | 4568 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2015 | 4043 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4751 | 0.050 |
Why?
|
Hirudins | 1 | 2021 | 183 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3255 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2008 | 3479 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3749 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2219 | 0.040 |
Why?
|
Recurrence | 1 | 2011 | 8340 | 0.040 |
Why?
|
Data Collection | 2 | 2022 | 3341 | 0.040 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2011 | 1813 | 0.040 |
Why?
|
Computational Biology | 1 | 2011 | 3521 | 0.040 |
Why?
|
Research Personnel | 1 | 2023 | 573 | 0.040 |
Why?
|
Area Under Curve | 1 | 2022 | 1654 | 0.040 |
Why?
|
Antithrombins | 1 | 2021 | 304 | 0.040 |
Why?
|
Receptor, erbB-2 | 1 | 2008 | 2416 | 0.040 |
Why?
|
Sweden | 1 | 2021 | 1345 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 3022 | 0.040 |
Why?
|
Shock, Cardiogenic | 1 | 2023 | 688 | 0.040 |
Why?
|
American Heart Association | 1 | 2022 | 1056 | 0.040 |
Why?
|
Thrombectomy | 1 | 2022 | 680 | 0.040 |
Why?
|
Electronic Mail | 1 | 2019 | 213 | 0.040 |
Why?
|
Cohort Studies | 3 | 2023 | 40561 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2008 | 5974 | 0.040 |
Why?
|
Aftercare | 1 | 2023 | 866 | 0.040 |
Why?
|
Piperazines | 1 | 2007 | 2488 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1681 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2021 | 1000 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2013 | 4838 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2023 | 77449 | 0.030 |
Why?
|
Phenotype | 2 | 2010 | 16365 | 0.030 |
Why?
|
Telephone | 1 | 2019 | 617 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2020 | 826 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 5751 | 0.030 |
Why?
|
Young Adult | 3 | 2012 | 56430 | 0.030 |
Why?
|
Hematopoietic Stem Cells | 1 | 2008 | 3386 | 0.030 |
Why?
|
Coronary Disease | 1 | 2010 | 6077 | 0.030 |
Why?
|
Gene Expression | 1 | 2008 | 7799 | 0.030 |
Why?
|
Pyrimidines | 1 | 2007 | 2942 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1619 | 0.030 |
Why?
|
ROC Curve | 1 | 2022 | 3527 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 9239 | 0.030 |
Why?
|
Decision Making, Organizational | 1 | 2014 | 139 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2065 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2023 | 1790 | 0.030 |
Why?
|
Pregnancy | 2 | 2020 | 29144 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2013 | 2016 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2008 | 3712 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2023 | 6538 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2022 | 5078 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2021 | 1772 | 0.030 |
Why?
|
Radiopharmaceuticals | 2 | 2013 | 2645 | 0.030 |
Why?
|
Vaccination | 1 | 2024 | 3278 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2023 | 25625 | 0.030 |
Why?
|
Apolipoprotein E2 | 1 | 2011 | 127 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2021 | 6622 | 0.020 |
Why?
|
Methionine | 1 | 2013 | 590 | 0.020 |
Why?
|
Patient Discharge | 1 | 2023 | 3313 | 0.020 |
Why?
|
Prosthesis Failure | 1 | 2016 | 1206 | 0.020 |
Why?
|
Incidence | 2 | 2021 | 20947 | 0.020 |
Why?
|
Adolescent | 4 | 2024 | 85781 | 0.020 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2011 | 365 | 0.020 |
Why?
|
Heart | 1 | 2023 | 4467 | 0.020 |
Why?
|
Hypergammaglobulinemia | 1 | 2009 | 74 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3952 | 0.020 |
Why?
|
Patient Readmission | 1 | 2023 | 3114 | 0.020 |
Why?
|
Greece | 1 | 2009 | 344 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12354 | 0.020 |
Why?
|
Apolipoprotein E4 | 1 | 2011 | 668 | 0.020 |
Why?
|
Infant | 2 | 2023 | 35136 | 0.020 |
Why?
|
Workload | 1 | 2013 | 850 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11524 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2011 | 935 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5137 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 2124 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 1530 | 0.020 |
Why?
|
Information Dissemination | 1 | 2013 | 1099 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 2011 | 1504 | 0.020 |
Why?
|
Child | 3 | 2023 | 77709 | 0.020 |
Why?
|
Pattern Recognition, Automated | 1 | 2011 | 1005 | 0.020 |
Why?
|
Prevalence | 2 | 2012 | 15226 | 0.010 |
Why?
|
Forecasting | 1 | 2013 | 2951 | 0.010 |
Why?
|
Heart Failure | 1 | 2008 | 10900 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2010 | 1275 | 0.010 |
Why?
|
Prospective Studies | 1 | 2007 | 53288 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8388 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2009 | 1381 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2015 | 6993 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2010 | 4186 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2011 | 2002 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2011 | 4420 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2014 | 4245 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2008 | 1339 | 0.010 |
Why?
|
Software | 1 | 2013 | 4443 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7149 | 0.010 |
Why?
|
Proteomics | 1 | 2011 | 3638 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10943 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2009 | 12245 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2011 | 13989 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2010 | 15076 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 41006 | 0.010 |
Why?
|
Time Factors | 1 | 2008 | 40075 | 0.000 |
Why?
|